*University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, Kentucky
†Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain
‡Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
§Department of Biostatistics, The University of Kansas Medical Center, Kansas City, Kansas.
Correspondence: Jose de Leon, MD, University of Kentucky Mental Health Research Center at Eastern State Hospital, 627 West Fourth St, Lexington, KY 40508 (e-mail: [email protected]).
No commercial organizations had any role in the writing of this article for publication. F. J. Diaz was supported by Frontiers: The Heartland Institute for Clinical and Translational Research CTSA UL1RR033179 (awarded to the University of Kansas Medical Center). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
J. de Leon personally develops his presentations for lecturing, has never lectured using any pharmaceutical or pharmacogenetic company presentation, and has never been a consultant for pharmacogenetic or pharmaceutical companies. In the past, J. de Leon has received researcher-initiated grants from Eli Lilly (one ended in 2003 and the other, as co-investigator, ended in 2007); from Roche Molecular Systems, Inc (ended in 2007); and, in a collaboration with Genomas, Inc, from the National Institutes of Health Small Business Innovation Research program (ended in 2010). He has been on the advisory boards of Bristol-Myers Squibb (2003/2004) and AstraZeneca (2003). Roche Molecular Systems supported one of his educational presentations, which was published in a peer-reviewed journal (2005). His lectures have been supported once by Sandoz (1997), twice by Lundbeck (1999 and 1999), twice by Pfizer (2001 and 2001), three times by Eli Lilly (2003, 2006, and 2006), twice by Janssen (2000 and 2006), once by Bristol-Myers Squibb (2006), and seven times by Roche Molecular Systems, Inc (once in 2005 and six times in 2006). In the past 3 years, E. Spina has participated in speakers/advisory boards and lectured supported by AstraZeneca, Boheringer-Ingelheim, Eli Lilly, Janssen, Lundbeck, Pfizer, and Servier. In the past 3 years, F. J. Diaz had no conflict of interest.
Received July 16, 2012
Accepted October 19, 2012
